Interpace Diagnostics ROE 2006-2018 | IDXG

Current and historical return on equity (ROE) values for Interpace Diagnostics (IDXG) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Interpace Diagnostics ROE for the three months ending September 30, 2018 was -33.67%.
Interpace Diagnostics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-0.01B $0.04B -33.55%
2018-06-30 $-0.01B $0.04B -33.55%
2018-03-31 $-0.02B $0.04B -44.74%
2017-12-31 $-0.01B $0.04B -35.04%
2017-09-30 $-0.00B $0.04B -3.85%
2017-06-30 $-0.01B $0.04B -29.85%
2017-03-31 $-0.00B $0.03B -10.81%
2016-12-31 $-0.01B $0.01B -160.00%
2016-09-30 $-0.01B $-0.00B -153.85%
2016-06-30 $-0.01B $0.01B -96.97%
2016-03-31 $-0.01B $0.01B -140.54%
2015-12-31 $-0.01B $0.01B -104.35%
2015-09-30 $-0.02B $0.01B -173.58%
2015-06-30 $-0.02B $0.01B -122.22%
2015-03-31 $-0.02B $0.02B -79.12%
2014-12-31 $-0.02B $0.02B -60.95%
2014-09-30 $-0.01B $0.03B -44.44%
2014-06-30 $-0.01B $0.03B -34.38%
2014-03-31 $-0.01B $0.03B -26.28%
2013-12-31 $-0.01B $0.03B -13.89%
2013-09-30 $-0.03B $0.04B -67.57%
2013-06-30 $-0.02B $0.04B -56.14%
2013-03-31 $-0.02B $0.04B -47.67%
2012-12-31 $-0.03B $0.04B -46.51%
2012-09-30 $-0.01B $0.06B -18.41%
2012-06-30 $-0.01B $0.06B -16.00%
2012-03-31 $-0.01B $0.06B -16.99%
2011-12-31 $-0.01B $0.06B -17.84%
2011-09-30 $-0.01B $0.07B -7.17%
2011-06-30 $-0.01B $0.07B -9.96%
2011-03-31 $-0.01B $0.07B -9.82%
2010-12-31 $-0.01B $0.07B -11.07%
2010-09-30 $-0.02B $0.07B -31.29%
2010-06-30 $-0.03B $0.07B -33.02%
2010-03-31 $-0.03B $0.07B -35.40%
2009-12-31 $-0.03B $0.08B -37.06%
2009-09-30 $-0.03B $0.09B -33.08%
2009-06-30 $-0.04B $0.10B -34.42%
2009-03-31 $-0.04B $0.10B -33.55%
2008-12-31 $-0.03B $0.11B -27.09%
2008-09-30 $-0.02B $0.12B -14.21%
2008-06-30 $-0.01B $0.13B -10.14%
2008-03-31 $-0.01B $0.14B -6.37%
2007-12-31 $-0.01B $0.14B -6.97%
2007-09-30 $-0.00B $0.14B -2.06%
2007-06-30 $0.00B $0.15B 0.68%
2007-03-31 $0.00B $0.15B 2.74%
2006-12-31 $0.01B $0.15B 8.30%
2006-09-30 $-0.01B $0.14B -9.20%
2006-06-30 $-0.02B $0.14B -11.81%
2006-03-31 $-0.01B $0.14B -8.70%
2005-12-31 $-0.02B $0.14B -12.22%
Sector Industry Market Cap Revenue
Medical Medical Services $0.029B $0.016B
Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.382B 11.45
ICON (ICLR) Ireland $7.220B 22.63
PRA Health Sciences (PRAH) United States $6.479B 26.45
Charles River Laboratories (CRL) United States $6.010B 21.07
Premier (PINC) United States $5.056B 17.16
INC Research Holdings (SYNH) United States $4.514B 18.22
HealthEquity (HQY) United States $3.874B 75.72
Teladoc (TDOC) United States $3.587B 0.00
NovoCure (NVCR) Jersey $3.317B 0.00
AMN Healthcare Services Inc (AMN) United States $2.641B 18.12
BioTelemetry (BEAT) United States $2.149B 37.97
Medpace Holdings (MEDP) United States $1.902B 23.53
IKang Healthcare (KANG) China $1.412B 70.10
Intrexon (XON) United States $1.138B 0.00
Healthways (TVTY) United States $1.070B 13.16
CareDx (CDNA) United States $1.067B 0.00
Natera (NTRA) United States $0.946B 0.00
China Cord Blood (CO) China $0.729B 20.00
Surgery Partners (SGRY) United States $0.612B 0.00
Apollo Medical Holdings (AMEH) United States $0.582B 0.00
Civitas Solutions (CIVI) United States $0.532B 9.66
Establishment Labs Holdings (ESTA) $0.485B 0.00
Cancer Genetics (CGIX) United States $0.015B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00